home / stock / mrna / mrna articles

MRNA Articles, Moderna Inc. - From 05/02/24

Stock Information
Company Name: Moderna Inc.
Stock Symbol: MRNA
Market: NASDAQ
Website: modernatx.com
Menu
MRNA MRNA Quote MRNA Short MRNA News MRNA Articles MRNA Message Board
Get MRNA Alerts

News, Short Squeeze, Breakout and More Instantly...
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market | Benzinga

U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index future...
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,100 Today | Benzinga

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 23.65% on an annualized basis producing an average annual return of 35.3...

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week | Benzinga

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...

What's Going On With Pfizer Stock On Thursday? | Benzinga

GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a...
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On? | Benzinga

Moderna Inc (NASDAQ:MRNA) shares are trading higher Wednesday after the company announced an ongoing collaboration with OpenAI. What To Know: Moder...

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown | Benzinga

Moderna Inc. (NASDAQ:MRNA) is set to clash with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) i...

Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff | Benzinga

On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates&n...
$1000 Invested In Moderna 5 Years Ago Would Be Worth This Much Today | Benzinga

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 22.81% on an annualized basis producing an average annual return of 35.1...

Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans | Benzinga

Famed COVID-19 vaccine maker Moderna Inc (NASDAQ:MRNA) has decided to pause its plans to construct a vaccine manufacturing...

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study | Benzinga

Shares of Moderna (NASDAQ: MRNA) rose 6.2% on Apr 9 after management announced encouraging data from a portion of an early-stage study on mRNA-4157...
Previous 10 Next 10